Background -Near-infrared (NIR) imaging of lymphatic drainage of injected indocyanine green (ICG) has emerged as a new technology for clinical imaging of lymphatic architecture and quantification of vessel function, offering better spatial and temporal resolution than competing imaging modalities. While NIR lymphatic imaging has begun to be reported in the literature, the technology is still in its infancy and its imaging capabilities have yet to be quantitatively characterized. The objective of this study, therefore, was to characterize the parameters of NIR lymphatic imaging to quantify its capabilities as a diagnostic tool for evaluating lymphatic disease. Methods -An NIR imaging system was developed using a laser diode for excitation, ICG as a fluorescent agent, and a CCD camera to detect emission. A tissue phantom with mock lymphatic vessels of known depths and diameters was used as an alternative to in vivo lymphatic vessels due to the greater degree of control with the phantom. Results and Conclusions -When dissolved in an albumin physiological salt solution (APSS) to mimic interstitial fluid, ICG experiences shifts in the excitation/emission wavelengths such that it is maximally excited at 805nm and produces peak fluorescence at 840nm. Premixing ICG with albumin induces greater fluorescence intensity, with the ideal concentration being: 900μM (60g/L) albumin and 193.5μM (150μg/mL) ICG. ICG fluorescence can be detected as deep as 6mm, but spatial resolution deteriorates severely below 3mm, thus skewing vessel geometry measurements. ICG packet travel, a common measure of lymphatic transport, can be detected as deep as 5mm.
INTRODUCTION
The lymphatic system plays a critical role in regulating tissue fluid balance by draining the interstitial space and preserving protein concentrations to maintain oncotic pressure 1 . If the natural function of the lymphatic system is disrupted, several pathologies can develop, most notably lymphedema, which often results in irreversible tissue damage presumably through the disruption of lymphatic transport, thus leading to subsequent interstitial fluid stagnation and lipid accumulation in the affected tissues 2 . However, our current understanding of the lymphatic vasculature pales in comparison with the blood vasculature, a phenomena that can partly be attributed to the lack of in vivo imaging techniques suitable for visualizing lymphatic vessels. In the case of lymphedema, in particular, a major limitation in the development of new treatments has been the lack of in vivo imaging diagnostics capable of quantifying differences in the dynamic pump function of lymphatic vessels in real-time. 3 Recently, the lymphatic system has garnered increased interest as its roles in tumor metastasis 4 , dermal drug delivery 5 , chronic inflammation 6 , and lipid transport 7 are beginning to be appreciated. With the new understanding of the role of lymphatic vessels in disease processes and therapies there is now a greater need for major advances in the diagnostic imaging tools available to adequately visualize and quantify lymphatic pump function. Since lymphatic flow is driven primarily through the contractility of collecting lymphatic vessels 8, 9 , the ability to quantify lymphatic pump function through the imaging of functional lymphatic contractions and fluid flow would greatly improve the understanding of lymphatic contractile physiology and enhance the diagnosis of disease states. However, the two traditional gold standards of clinical lymphatic imaging, lymphoscintigraphy and magnetic resonance imaging (MRI), while very effective for systemic lymphatic mapping, are inadequate for the assessment of lymphatic function because draining vessels are below the spatial resolution of MRI and lymphoscintigraphy lacks the real-time temporal resolution needed to image the dynamics of lymphatic contractile function [10] [11] [12] [13] . Near-infrared (NIR) imaging technologies may provide the ideal solution to functional lymphatic imaging as both a research tool and a disease diagnostic because NIR light resides in the optimal wavelength range where light absorption and scattering are low in biological tissue and there is minimal autofluorescence, thus affording deeper penetration depths and properties 14 
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ICG Spectrum and Fluorescence
The NIR lymphatic imaging system that we developed in this study represents a departure from the setup of many of the NIR lymphatic imaging systems previously reported in that we pre-mixed ICG with albumin, and our system used an excitation wavelength of 808nm and emission wavelengths centered at 840nm 18, 21 . Our results indicate that ICG produces more than a three-fold increase in fluorescence when it binds to albumin, and the peak excitation and emission wavelengths are 805nm and 840nm respectively. The same effect is observed when ICG is introduced in APSS, thus suggesting that ICG binds to albumin in the interstitial space. Therefore, ICG-based NIR lymphatic imaging systems should excite at 805nm and capture emission centered at 840nm.
Tissue Phantom Sensitivity Analysis
According to our tissue phantom sensitivity analysis, the NIR lymphatic imaging system was capable of detecting ICG fluorescence as deep as 6mm. However, scattering effects resulted in a deterioration of spatial resolution with increasing depth, and geometric vessel features became difficult to accurately identify below a depth of 3mm. These results suggest that the NIR lymphatic imaging system is best used to detect vessel geometry and architecture above a 3mm depth, but an assessment of gross ICG accumulation and transport in vivo can be obtained as deep as 6mm. Given that the average human skin layer is between 1mm and 3mm thick 29 , these imaging characteristics are well-suited for imaging dermal lymphatic function. Most NIR lymphatic imaging is performed giving an intradermal ICG injection and monitoring transport through dermal collecting vessels, which we have validated can be achieved with our device with a high degree of accuracy. Future work to enhance the device should focus on the implementation of diffusion theory (e.g. using a Monte Carlo approach to predict light propagation through a tissue of known optical properties) to predict scattering effects and recreate a more accurate image of vessel geometry at various depths 30 .
Our tissue phantom sensitivity testing also showed packet tracking to be a very accurate method to calculate lymph velocity in vivo at a depth up to 5mm as our collective error was less than 1% over a range of velocities. It should be noted, however, that these measurements were obtained under ideal conditions in a tissue phantom, and the measurement process in vivo is more challenging. It is expected that the accuracy of this approach is reduced slightly in vivo as a result of valve function and inconsistent contractile events, but given the near perfect accuracy in a tissue phantom, the technique should be considered a good approach to obtain general approximations of average lymph velocity.
